FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551946455> ?p ?o ?g. }

• W2551946455 abstract "Background Certolizumab pegol (CZP) is a PEGylated Fab9 fragment of a humanized anti-TNF antibody and it brings rapid improvement of the signs and symptoms of RA. Musculoskeletal ultrasound (US) has been proved to be useful at assessing synovitis precisely in patients with RA. There are few reports, however, that verify the early response to CZP in RA patients by US. Moreover, it remains to be ascertained whether early US assessment of synovitis can predict future clinical response in treatment with CZP. Objectives In the present study we investigate whether US is useful for predicting future clinical response to CZP in RA patients. Methods Twenty patients with RA were treated with subcutaneous CZP 400 mg at weeks 0, 2, 4 followed by 400 mg every 4 weeks or 200 mg every 2 weeks. The mean age of patients was 55.2 years old and the mean disease duration was 5.9 years. The mean disease activity at baseline (week 0) was 4.91 for 28-joint disease activity score (DAS28). Fifteen (75%) patients were naive to biologic agents. Seventeen (85%) and 9 (36%) patients were treated with methotrexate and glucocorticoids concurrently. At baseline and weeks 2, 4 and 12, US examination was performed at bilateral MCP, PIP, IP, and wrist joints. Gray-scale (GS) and pulse Doppler (PD) signal was recorded in each joint using semi-quantitative score (0 to 3). The sum of these scores obtained from each joint was used as GSUS and PDUS score. Results At weeks 0, 2, 4, and 12, mean GSUS score was 24.1, 20.4, 17.5, and 16.7, respectively. Mean PDUS score at weeks 0, 2, 4, and 12, was 14.6, 10.8, 10.8, and 9.9, respectively. Both GSUS and PDUS score were improved significantly as early as 2 weeks after treatment (p=0.031 and 0.011) and reduced by degrees during study period. At weeks 0, 4, 8, 12, and 24, mean DAS28 was 4.91, 3.61, 3.55, 3.50, and 3.05, respectively. DAS28 was significantly improved as early as 4 weeks after treatment (p 50% reduction in PDUS score from baseline (PDUS 50 response) at week 2. At week2, none achieved a >50% reduction of GSUS score from baseline, whereas 8 patients indicated a >20% reduction in GSUS score from baseline (GSUS 20 response) at week 2. There was a marked high responder rate (80%: 4 out of 5) in the patients showing PDUS 50 response at week 2. Similarly, the responder rate (88%: 7 out of 8) of the patients showing GSUS 20 response at week 2 was remarkably high and significantly higher than that (25%: 3 out of 12, p=0.020) of the patients without GSUS 20 response. Conclusions Early response to CZP was confirmed by US examination and the early assessment of synovitis by US is useful to predict future clinical response to CZP in patients with RA. Disclosure of Interest None declared" @default.
• W2551946455 created "2016-11-30" @default.
• W2551946455 creator A5000358315 @default.
• W2551946455 creator A5009219056 @default.
• W2551946455 creator A5031821817 @default.
• W2551946455 creator A5051406303 @default.
• W2551946455 creator A5054296527 @default.
• W2551946455 creator A5056319907 @default.
• W2551946455 creator A5071151801 @default.
• W2551946455 creator A5078572977 @default.
• W2551946455 creator A5082187394 @default.
• W2551946455 creator A5086768780 @default.
• W2551946455 date "2016-06-01" @default.
• W2551946455 modified "2023-09-27" @default.
• W2551946455 title "AB0331 Early Improvement of Musculoskeletal Ultrasound Findings Can Predict Future Clinical Response To Certolizumab Pegol in Patients with Rheumatoid Arthritis" @default.
• W2551946455 doi "https://doi.org/10.1136/annrheumdis-2016-eular.1909" @default.
• W2551946455 hasPublicationYear "2016" @default.
• W2551946455 type Work @default.
• W2551946455 sameAs 2551946455 @default.
• W2551946455 citedByCount "0" @default.
• W2551946455 crossrefType "journal-article" @default.
• W2551946455 hasAuthorship W2551946455A5000358315 @default.
• W2551946455 hasAuthorship W2551946455A5009219056 @default.
• W2551946455 hasAuthorship W2551946455A5031821817 @default.
• W2551946455 hasAuthorship W2551946455A5051406303 @default.
• W2551946455 hasAuthorship W2551946455A5054296527 @default.
• W2551946455 hasAuthorship W2551946455A5056319907 @default.
• W2551946455 hasAuthorship W2551946455A5071151801 @default.
• W2551946455 hasAuthorship W2551946455A5078572977 @default.
• W2551946455 hasAuthorship W2551946455A5082187394 @default.
• W2551946455 hasAuthorship W2551946455A5086768780 @default.
• W2551946455 hasConcept C126322002 @default.
• W2551946455 hasConcept C141071460 @default.
• W2551946455 hasConcept C198451711 @default.
• W2551946455 hasConcept C2776215756 @default.
• W2551946455 hasConcept C2777077863 @default.
• W2551946455 hasConcept C2777575956 @default.
• W2551946455 hasConcept C2778216619 @default.
• W2551946455 hasConcept C2779244835 @default.
• W2551946455 hasConcept C2779338263 @default.
• W2551946455 hasConcept C2779605438 @default.
• W2551946455 hasConcept C2780132546 @default.
• W2551946455 hasConcept C2780653079 @default.
• W2551946455 hasConcept C2781059491 @default.
• W2551946455 hasConcept C71924100 @default.
• W2551946455 hasConceptScore W2551946455C126322002 @default.
• W2551946455 hasConceptScore W2551946455C141071460 @default.
• W2551946455 hasConceptScore W2551946455C198451711 @default.
• W2551946455 hasConceptScore W2551946455C2776215756 @default.
• W2551946455 hasConceptScore W2551946455C2777077863 @default.
• W2551946455 hasConceptScore W2551946455C2777575956 @default.
• W2551946455 hasConceptScore W2551946455C2778216619 @default.
• W2551946455 hasConceptScore W2551946455C2779244835 @default.
• W2551946455 hasConceptScore W2551946455C2779338263 @default.
• W2551946455 hasConceptScore W2551946455C2779605438 @default.
• W2551946455 hasConceptScore W2551946455C2780132546 @default.
• W2551946455 hasConceptScore W2551946455C2780653079 @default.
• W2551946455 hasConceptScore W2551946455C2781059491 @default.
• W2551946455 hasConceptScore W2551946455C71924100 @default.
• W2551946455 hasLocation W25519464551 @default.
• W2551946455 hasOpenAccess W2551946455 @default.
• W2551946455 hasPrimaryLocation W25519464551 @default.
• W2551946455 isParatext "false" @default.
• W2551946455 isRetracted "false" @default.
• W2551946455 magId "2551946455" @default.
• W2551946455 workType "article" @default.